Scarica l'app Stockscreener
491.47
5.69%
26.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Assetmark Inc. Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Ins - GuruFocus
Vertex veers upwards on impressive results - The Pharma Letter
Vertex Pharmaceuticals Signals Confident Growth Beyond CF - TipRanks
Vertex’s CRISPR therapy rebounds in latest earnings - BioPharma Dive
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 - The Motley Fool
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase - Finviz
Vertex Pharmaceuticals (VRTX): Scotiabank Raises Price Target to $558 | VRTX Stock News - GuruFocus
RBC Capital Lowers Vertex Pharmaceuticals' (VRTX) Price Target | - GuruFocus
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - Finviz
Vertex Pharmaceuticals (VRTX) Analyst Maintains Rating and Raises Price Target | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says - marketscreener.com
Top Biotech Stocks To ConsiderFebruary 13th - MarketBeat
Busy with Casgevy and Journavx launches, Vertex sets ambitious $500M revenue goal for non-CF meds this year - Fierce Pharma
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Topline Grows 10% - FXDailyReport.Com
Vertex Prepares Povetacicept For APRIL/BAFF Battle - Citeline News & Insights
Agree To Purchase Vertex Pharmaceuticals At $320, Earn 4.4% Using Options - Nasdaq
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp - BioSpace
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - Finviz
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News - GuruFocus
Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays - Insider Monkey
AI for investors - MLQ.ai
Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts Vertex Pharmaceuticals Price Target to $577 From $572, Maintains Outperform Rating - marketscreener.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to "Outperform" at Oppenheimer - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Vertex Pharma Q4 2025 Earnings Results - AlphaStreet News
All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts - BioSpace
Vertex Pharmaceuticals (VRTX) Receives Boosted Price Target from HC Wainwright & Co. | VRTX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 11 Analysts - Benzinga
11,989 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by ING Groep NV - MarketBeat
Atria Investments Inc Acquires 2,418 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highligh - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock Drops After Hours — Here's Why It's Trending Tonight - Benzinga
Vertex Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance - Intellectia AI
Vertex Pharmaceuticals (VRTX) Reports Strong Q4 2025 Revenue Growth - GuruFocus
Vertex Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Mark Bunnage Sells 2,021 Shares - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 1,751 Shares of Stock - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 466 Shares of Stock - MarketBeat
Vertex Pharmaceuticals (VRTX) Reports Mixed Q4 Results with Stro - GuruFocus
How Vertex Pharmaceuticals Incorporated stock responds to policy changesOptions Play & Daily Stock Momentum Reports - mfd.ru
VRTX: 2025 delivered robust growth and diversification, with 2026 set for further expansion and innovation - TradingView
Earnings call transcript: Vertex Q4 2025 sees revenue growth, EPS miss - Investing.com
Vertex Pharmaceuticals (NASDAQ:VRTX) CAO Sells $633,551.68 in Stock - MarketBeat
Vertex Pharmaceuticals (VRTX) Q4 Earnings Miss Estimates - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Surpasses Q4 Revenue Expectations - GuruFocus
Vertex Pharma Q4 revenue rises 10% YoY, but earnings miss analyst expectations - Investing.com Australia
Vertex Q4 results miss on bottom line; 2026 revenue guidance in-line - Seeking Alpha
Vertex Pharmaceuticals falls after Q4 profit miss - TradingView
Vertex Pharmaceuticals (NASDAQ:VRTX) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Vertex Pharmaceuticals's (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue - Finviz
Vertex: Q4 Earnings Snapshot - kare11.com
Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Reports Q4 Revenue $3.19B, vs. FactSet Est of $3.18B - marketscreener.com
Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q4 Adjusted EPS $5.03, vs. FactSet Est of $5.11 - marketscreener.com
Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q4 Adjusted EPS $5.03 per Share, vs. FactSet Est of $5.11 - marketscreener.com
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue - Yahoo Finance
Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line - Nasdaq
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
Vertex Pharma’s Precision Bet: How Vertex Is Rewriting the Rulebook for Biotech Blockbusters - AD HOC NEWS
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term - Nasdaq
12,843 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Leuthold Group LLC - MarketBeat
Rhumbline Advisers Has $175.43 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Drops After HoursHere's Why It's Trending Tonight - Bitget
Cystic Fibrosis Market to hit US$ 26.58 Billion by 2031 | Major - openPR.com
Vertex Pharmaceuticals (VRTX) Q4 Earnings Preview: Key Expectati - GuruFocus
Biotech Stocks To Add to Your WatchlistFebruary 11th - MarketBeat
Vertex Pharmaceuticals's Earnings Outlook - Benzinga
2.49%
1.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):